Syneos Health Signs Agreement with Kyushu University Hospital to Support Clinical Trials in Japan
January 21, 2025
MORRISVILLE, N.C., January 21, 2025 - Syneos Health®, a leading fully integrated biopharmaceutical solutions organization, has signed an agreement with Kyushu University Hospital. The agreement expands the Company’s clinical trial capabilities across a broad range of therapeutic areas in Japan.
Kyushu University Hospital now becomes part of the Syneos Health Catalyst and Site Network Partnerships program, including 110+ clinical sites and 60+ commercial site networks. As part of the Site Network Partnerships program, Kyushu University Hospital joins a select set of high-performing investigative site networks strategically aligned to the Company’s clinical studies. Site Network Partnerships provide enhanced patient access, improved efficiencies, specialized expertise and access to diverse patient populations across all therapeutic areas and phases.
"The agreement with Kyushu University Hospital is a key component of the global strategy at Syneos Health to enhance our clinical development capabilities in this dynamic and rapidly evolving market," said Stephane Gouteux, Vice President & General Manager, Japan, Syneos Health. "This work underscores our commitment to delivering exceptional value to customers by providing consistent, high-quality results and tailored solutions that meet their unique and complex requirements."
The roots of Kyushu University Hospital can be traced back more than 150 years. Now ranked in the top five hospitals in Japan for four consecutive years in Newsweek’s World’s Best Hospitals 2024 and top 100 worldwide, Kyushu University Hospital is one of Japan’s foremost university hospitals in both name and practice.
As a primary center providing a wide range of advanced medical services in western Japan, Kyushu University Hospital is fully capable of conducting both challenging global and early phase trials. The hospital’s participation in the Catalyst and Site Network Partnerships program will contribute to the improvement of the quality and volume of clinical trials in Japan. The hospital has already initiated new projects since joining the program resulting in the acceleration of study start-up and the delivery of more accurate trials.
About Syneos Health
Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities.
We bring together a talented team of professionals with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.
Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.
To learn more about how we are Shortening the distance from lab to life®, visit syneoshealth.com.
Press/Media Contact:
Meg Byers
Director, External Communications
+1 607 215 1330
“Further, this collaboration will not affect ACTIVATO’S reviewing process. Our trial management office will continue to act independently from the reviewing office, and guide sponsors and sites to streamline and optimize the process and timeline,” added Murao.
About Syneos Health
Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities.
We bring together a talented team of professionals with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.
Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.
To learn more about how we are Shortening the distance from lab to life®, visit syneoshealth.com.
Press/Media Contact:
Meg Byers
Director, External Communications
+1 607 215 1330[email protected]
